Marine Natural Products as Breast Cancer Resistance Protein Inhibitors
AbstractBreast cancer resistance protein (BCRP) is a protein belonging to the ATP-binding cassette (ABC) transporter superfamily that has clinical relevance due to its multi-drug resistance properties in cancer. BCRP can be associated with clinical cancer drug resistance, in particular acute myelogenous or acute lymphocytic leukemias. The overexpression of BCRP contributes to the resistance of several chemotherapeutic drugs, such as topotecan, methotrexate, mitoxantrone, doxorubicin and daunorubicin. The Food and Drugs Administration has already recognized that BCRP is clinically one of the most important drug transporters, mainly because it leads to a reduction of clinical efficacy of various anticancer drugs through its ATP-dependent drug efflux pump function as well as its apparent participation in drug resistance. This review article aims to summarize the different research findings on marine natural products with BCRP inhibiting activity. In this sense, the potential modulation of physiological targets of BCRP by natural or synthetic compounds offers a great possibility for the discovery of new drugs and valuable research tools to recognize the function of the complex ABC-transporters. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Cherigo, L.; Lopez, D.; Martinez-Luis, S. Marine Natural Products as Breast Cancer Resistance Protein Inhibitors. Mar. Drugs 2015, 13, 2010-2029.
Cherigo L, Lopez D, Martinez-Luis S. Marine Natural Products as Breast Cancer Resistance Protein Inhibitors. Marine Drugs. 2015; 13(4):2010-2029.Chicago/Turabian Style
Cherigo, Lilia; Lopez, Dioxelis; Martinez-Luis, Sergio. 2015. "Marine Natural Products as Breast Cancer Resistance Protein Inhibitors." Mar. Drugs 13, no. 4: 2010-2029.